公开(公告)号：US20170182123A1

公开(公告)日：2017-06-29

申请号：US15316108

申请日：2015-06-15

申请人： NGM Biopharmaceuticals, Inc.

发明人： Lei LING ,  Hui TIAN

IPC分类号： A61K38/18 ,  A61K45/06

CPC分类号： A61K38/1825 ,  A61K31/155 ,  A61K31/165 ,  A61K31/519 ,  A61K31/52 ,  A61K31/573 ,  A61K31/575 ,  A61K31/64 ,  A61K38/13 ,  A61K38/208 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  C07K14/50 ,  C07K2319/00 ,  A61K2300/00

摘要： Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.

公开(公告)号：US20200164036A1

公开(公告)日：2020-05-28

申请号：US16562150

申请日：2019-09-05

申请人： NGM Biopharmaceuticals, Inc.

发明人： Alexander Mark DEPAOLI ,  Jian LUO ,  Hui TIAN

IPC分类号： A61K38/18 ,  G01N33/68 ,  G01N33/50 ,  A61P1/00 ,  G01N33/92

摘要： Provided herein are methods of using 7α-hydroxy-4-cholesten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).

公开(公告)号：US20180110834A1

公开(公告)日：2018-04-26

申请号：US15524896

申请日：2015-11-06

申请人： NGM Biopharmaceuticals, Inc.

发明人： Alexander Mark DEPAOLI ,  Jian LUO ,  Hui TIAN

IPC分类号： A61K38/18 ,  G01N33/92 ,  A61P1/00 ,  G01N33/50

CPC分类号： A61K38/1825 ,  A61P1/00 ,  G01N33/5088 ,  G01N33/6848 ,  G01N33/92 ,  G01N2405/00 ,  G01N2800/08 ,  G01N2800/52

摘要： Provided herein are methods of using 7a-hydroxy-4-cholsten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).

公开(公告)号：US20170299608A1

公开(公告)日：2017-10-19

申请号：US15449841

申请日：2017-03-03

申请人： NGM Biopharmaceuticals, Inc.

发明人： Jer-Yuan HSU ,  Yu CHEN ,  Suzanne Christine CRAWLEY ,  Hui TIAN ,  Wenyan SHEN ,  Jie TANG ,  Jared Martin HIGBEE

IPC分类号： G01N33/68 ,  G06F19/16 ,  C07K16/22 ,  C07K14/495 ,  C07K16/28 ,  C07K14/71 ,  G01N33/50

CPC分类号： G01N33/6854 ,  A61K38/00 ,  C07K14/495 ,  C07K14/71 ,  C07K16/22 ,  C07K16/2863 ,  C07K2299/00 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/6897 ,  G01N33/5008 ,  G01N2500/02 ,  G16B15/00

摘要： The present disclosure provides a protein complex, including a three-dimensional structure of the protein complex, that plays a role in regulation of body weight. In addition, the protein complex and components thereof, including three-dimensional structures thereof, find use in identifying agents that can be used to control body weight.

公开(公告)号：US20220241373A1

公开(公告)日：2022-08-04

申请号：US17562732

申请日：2021-12-27

申请人： NGM Biopharmaceuticals, Inc.

发明人： Lei LING ,  Hui TIAN

IPC分类号： A61K38/18 ,  A61K45/06 ,  C07K14/50 ,  A61K38/13 ,  A61K38/20 ,  A61K38/28 ,  A61K38/26 ,  A61K31/519 ,  A61K31/155 ,  A61K31/52 ,  A61K31/575 ,  A61K31/165 ,  A61K31/64 ,  A61K31/573

摘要： Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.

公开(公告)号：US20220072099A1

公开(公告)日：2022-03-10

申请号：US17472309

申请日：2021-09-10

申请人： NGM Biopharmaceuticals, Inc.

发明人： Alexander Mark DEPAOLI ,  Jian LUO ,  Hui TIAN

IPC分类号： A61K38/18 ,  G01N33/92 ,  G01N33/68 ,  A61P1/00 ,  G01N33/50

摘要： Provided herein are methods of using 7α-hydroxy-4-cholesten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).